FDA Approval Mifepristone REMS Program Modification Expands Patient Access to Abortion Care By Justine Lei on January 20, 2023 Posted in Drug and Pharmaceutical Law, FDA, Healthcare The Food and Drug Administration (the “FDA”) has approved a modification to the Mifepristone Risk Evaluation and Mitigation Strategy (“REMS”) Program, increasing the accessibility of mifepristone for patients with a prescription. [1], [2] … Continue Reading FDA Approval Mifepristone REMS Program Modification Expands Patient Access to Abortion Care
